
    
      This is a phase II efficacy trial for patients with untreated, high-risk, B-cell
      Non-Hodgkin's Lymphoma. The study will evaluate the efficacy and safety of high-dose
      chemotherapy combined with monoclonal antibodies and targeted radioimmunotherapy in
      previously untreated patients with high-risk NHL
    
  